<DOC>
	<DOCNO>NCT02769130</DOCNO>
	<brief_summary>This pilot study evaluate safety feasibility losartan pediatric patient pulmonary vein stenosis . It open label single arm interventional study . The patient population involve pediatric patient stenosis 2 pulmonary vein . Patients give losartan 1 year . Outcomes include measure safety/adverse event progression pulmonary vein stenosis .</brief_summary>
	<brief_title>Pilot Trial : Safety Feasibility Losartan Pulmonary Vein Stenosis</brief_title>
	<detailed_description>This pilot study evaluate safety feasibility losartan pediatric patient pulmonary vein stenosis . Large animal study demonstrate losartan ameliorate progression pulmonary vein stenosis surgical model pulmonary vein stenosis . There safety data losartan child &lt; 6months age child pulmonary vein stenosis . Therefore , study test safety feasibility losartan child open label single arm interventional study . Patient inclusion criterion include stenosis involve 2 pulmonary vein . Patients consent trial losartan therapy one year . They undergo study visit every 3 month . Patients screen adverse event biochemical test , routine clinical test questionnaire . An exploratory efficacy analysis compare progression pulmonary vein stenosis child enrol losartan contemporary cohort child pulmonary vein stenosis , receive losartan .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Stenosis involve 2 pulmonary vein Consent parent/legal guardian child ( appropriate ) History angioedema allergic reaction angiotensin convert enzyme inhibitor correct gestational age le 40 week severe renal dysfunction pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>